INSR and Hyperglycemia: (Supplementary Table 3) The results revealed that it was much less potent than AZD9291 against both INSR (GI50: 2.8μM versus 0.5 μM) and IGF1R (GI50: 3.6 μM versus 0.56 μM) indicating that there was much less chance that this drug could induce the hyperglycemia adverse effects.